These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 9814448)

  • 1. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
    Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
    Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
    Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
    Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
    Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
    Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment.
    Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
    Thyroid; 2005 Apr; 15(4):358-63. PubMed ID: 15876160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
    Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
    J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
    Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
    Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy.
    Ujhelyi B; Erdei A; Galuska L; Varga J; Szabados L; Balazs E; Bodor M; Cseke B; Karanyi Z; Leovey A; Mezosi E; Burman KD; Berta A; Nagy EV
    Thyroid; 2009 Apr; 19(4):375-80. PubMed ID: 19355827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
    Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
    Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos.
    Mansi L; Rambaldi PF; Bizzarro A; Panza N; Di Martino S; De Bellis A; Del Vecchio E
    Q J Nucl Med; 1995 Jun; 39(2):105-10. PubMed ID: 8574802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
    Kung AW; Michon J; Tai KS; Chan FL
    Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of octreoscan and correlation with MR imaging in Graves' ophthalmopathy.
    Kahaly G; Diaz M; Just M; Beyer J; Lieb W
    Thyroid; 1995 Apr; 5(2):107-11. PubMed ID: 7647569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].
    Ardjomand N; Esche G; Fellner P; Lindner S; Panzitt M; Aigner R; Langmann A
    Ophthalmologe; 2003 Dec; 100(12):1049-53. PubMed ID: 14704818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [[111In]-DTPA-D-phenylalanine octreotide SPECT for the scintigraphic imaging of enhanced somatostatin-receptor density in endocrine ophthalmopathy].
    Cordes M; Hosten N; Gräf KJ; Wenzel KW; Venz S; Keske U; Eichstädt H; Felix R
    Rofo; 1994 Jan; 160(1):11-5. PubMed ID: 8305685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy].
    Duan L; Li XF; Lu KY; Zhang CG; Hu G; Liu JZ; Li SJ
    Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1068-72. PubMed ID: 17415962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Am J Ophthalmol; 2003 Mar; 135(3):285-90. PubMed ID: 12614743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.